Drug intelligence / Profile preview

ceftriaxone sodium + cefuroxime axetil

Development stage: Unknown
Lead developer: Roche
Modality: Small Molecules
Administration: Intravenous, Intramuscular, Oral

Overview

This is a combination of two cephalosporin antibiotics. Ceftriaxone sodium is a third-generation cephalosporin administered parenterally (IV/IM), while cefuroxime axetil is a second-generation cephalosporin administered orally. Both antibiotics work by inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins, preventing the final transpeptidation step needed for peptidoglycan cross-linking. This combination might be used for sequential therapy, starting with parenteral ceftriaxone followed by oral cefuroxime axetil.

Targets

PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on ceftriaxone sodium + cefuroxime axetil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ceftriaxone sodium + cefuroxime axetil.

Explore the full profile